Teradyne price target raised to $101 from $92 at Morgan Stanley

Morgan Stanley analyst Joseph Moore raised the firm’s price target on Teradyne (TER) to $101 from $92 and keeps an Equal Weight rating on the shares. Teradyne guided lower for the March quarter and indicated that tougher conditions will persist through the first half, which is "not surprising," although the firm had thought that Apple (AAPL) might be a bigger offset to headwinds. The firm notes that its estimates for the March quarter increased slightly after the report and guidance given stronger revenues and EPS than expected.